Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease
- PMID: 17368428
- DOI: 10.1016/j.brainres.2007.02.028
Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease
Abstract
The developmental biology of the dopamine (DA) system may hold important clues to its reconstruction. We hypothesized that factors highly expressed during nigrostriatal development and re-expressed after injury and disease may play a role in protection and reconstruction of the nigrostriatal system. Examination of gene expression in the developing striatum suggested an important role for the heparin binding growth factor family at time points relevant to establishment of dopaminergic innervation. Midkine, pleiotrophin (PTN), and their receptors syndecan-3 and receptor protein tyrosine phosphatase beta/zeta, were highly expressed in the striatum during development. Furthermore, PTN was up-regulated in the degenerating substantia nigra of Parkinson's patients. The addition of PTN to ventral mesencephalic cultures augmented DA neuron survival and neurite outgrowth. Thus, PTN was identified as a factor that plays a role in the nigrostriatal system during development and in response to disease, and may therefore be useful for neuroprotection or reconstruction of the DA system.
Similar articles
-
The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system.Brain Res Rev. 2007 Apr;54(1):80-91. doi: 10.1016/j.brainresrev.2006.12.001. Epub 2007 Jan 16. Brain Res Rev. 2007. PMID: 17229467 Review.
-
Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: analysis of suppression-subtracted cDNA libraries and confirmation in vitro.Exp Neurol. 2005 Jul;194(1):243-54. doi: 10.1016/j.expneurol.2005.02.015. Exp Neurol. 2005. PMID: 15899261
-
Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.Brain Behav Immun. 2009 May;23(4):518-26. doi: 10.1016/j.bbi.2009.01.018. Epub 2009 Feb 7. Brain Behav Immun. 2009. PMID: 19486644
-
Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice.Brain Res. 2005 Mar 28;1039(1-2):177-88. doi: 10.1016/j.brainres.2005.01.052. Brain Res. 2005. PMID: 15781060
-
Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development.Neurosci Biobehav Rev. 2007;31(3):287-314. doi: 10.1016/j.neubiorev.2006.09.008. Epub 2006 Dec 4. Neurosci Biobehav Rev. 2007. PMID: 17141870 Review.
Cited by
-
Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.Br J Pharmacol. 2014 Feb;171(4):837-48. doi: 10.1111/bph.12312. Br J Pharmacol. 2014. PMID: 23889475 Free PMC article. Review.
-
Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.Front Cell Neurosci. 2015 Jan 8;8:443. doi: 10.3389/fncel.2014.00443. eCollection 2014. Front Cell Neurosci. 2015. PMID: 25620911 Free PMC article. Review.
-
The expression and function of midkine in the vertebrate retina.Br J Pharmacol. 2014 Feb;171(4):913-23. doi: 10.1111/bph.12495. Br J Pharmacol. 2014. PMID: 24460673 Free PMC article. Review.
-
Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.J Neural Transm (Vienna). 2011 Aug;118(8):1215-25. doi: 10.1007/s00702-010-0568-3. Epub 2011 Feb 8. J Neural Transm (Vienna). 2011. PMID: 21301897
-
Structural studies reveal an important role for the pleiotrophin C-terminus in mediating interactions with chondroitin sulfate.FEBS J. 2016 Apr;283(8):1488-503. doi: 10.1111/febs.13686. Epub 2016 Mar 6. FEBS J. 2016. PMID: 26896299 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical